COMMUNIQUÉS West-GlobeNewswire

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference
23/10/2024
October 23, 2024 News Release BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, October 23, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto [...]
Rapafusyn Announces an Upcoming Oral Presentation at Targeted Protein Degradation & Induced Proximity Summit
23/10/2024
BALTIMORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce an upcoming oral presentation at the 7 th Targeted Protein Degradation & Induced Proximity Summit taking place from [...]
Le KFSHRC s’impose comme le plus important programme de transplantation rénale par don croisé au monde, avec 500 transplantations réussies
23/10/2024
Le centre consolide son rôle de leader en tant que fournisseur de solutions innovantes pour les patients atteints d’insuffisance rénale RIYAD, Arabie saoudite, 23 oct. 2024 (GLOBE NEWSWIRE) -- Dans le cadre de son [...]
KFSHRC Performs World First Robotic Left Liver Lobe Transplant
23/10/2024
Novel Technique Hopes to Extend Robotic Transplant to More Patients RIYADH, Saudi Arabia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has achieved another world first [...]
Bloo Pharmapeutica Introduces Age-Defying Methylene Blue Bath Solution: Aqua Miraculorum “Water of Miracles”
23/10/2024
Serious Help for Aging Skin, Now Available Online and in Select Retailers Vancouver, B.C., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bloo Pharmapeutica Inc. , an innovator in science-based health and wellness solutions, is [...]
HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
23/10/2024
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and [...]
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
23/10/2024
- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities - BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, [...]
Humber River Health Embarks on $100 Million Fundraising Mission to Cure Healthcare
23/10/2024
Funding to support blueprint for new high-quality, innovative models of care in Canada and beyond TORONTO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Canadians take great pride in their universal healthcare system, but with [...]
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
23/10/2024
GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Outset Medical to Report Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
23/10/2024
SAN JOSE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23/10/2024
Oral gildeuretinol demonstrated a statistically significant reduction in the geographic atrophy (GA) lesion growth rate of 15.3% from 6 to 24 months (p=0.047) in a pre-specified analysis. Gildeuretinol is the first [...]
Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024
23/10/2024
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
VIVUS Announces Label Update for QSYMIA®
23/10/2024
– QSYMIA ® is the leading once-daily oral branded, weight-management medication – – First head-to-head randomized placebo-controlled study of QSYMIA ® and phentermine demonstrating reductions in ambulatory blood [...]
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
23/10/2024
Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD) THE WOODLANDS, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new [...]
Visory Health Announces Folds of Honor Partnership to Bring Affordable Medications to Veterans
23/10/2024
The health tech company is providing access to discounted medication to the millions of military Veterans in the U.S., their immediate families, and all those who supports Veterans ESTERO, Fla., Oct. 23, 2024 (GLOBE [...]
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
23/10/2024
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- [...]
Major shareholder announcement
23/10/2024
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
23/10/2024
WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
23/10/2024
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]

Pages